Search Results
May 17, 2026, 21:13 ET El Día de la Innovación de ACROBiosystems llega a Zúrich
enzimas. En su ponencia titulada "Enzimas inmovilizadas para la fabricación inteligente de productos biológicos: aplicaciones en la producción de ARNm y ADC", presentaron una tecnología patentada que mejora la estabilidad y la reutilización de las enzimas. Presentaron dos estudios de caso: la inmovilización
More news about: ACROBiosystems Group
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
Herstellung durch die Immobilisierung von Enzymen. In ihrem Vortrag „Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production" stellten sie eine patentierte Technologie vor, die die Stabilität und Wiederverwendbarkeit von Enzymen erhöht. Sie stellten zwei Fallstudien
More news about: ACROBiosystems Group
May 17, 2026, 21:10 ET Zurich accueille la journée de l'innovation d'ACROBiosystems : les plus grands esprits s'unissent pour explorer les frontières de la biotechnologie
fabrication par immobilisation des enzymes. Dans leur exposé intitulé « Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production » (Les enzymes immobilisés pour une fabrication intelligente des médicaments biologiques : applications dans la production d'ARNm et d'ADC),
More news about: ACROBiosystems Group
May 15, 2026, 17:00 ET TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
and development plan for our VISTA inhibitor, TBS-2025, and initiating a Phase 1b/2 trial of TBS-2025 in mutNPM1 r/r AML; selecting our lead ADC for proof-of-concept studies in AML; and completing enrollment in our Phase 3 study of IFx-2.0 in Merkel Cell Carcinoma (MCC)."First Quarter
More news about: TuHURA Biosciences, Inc.
May 15, 2026, 08:00 ET Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual
More news about: Whitehawk Therapeutics, Inc.
May 15, 2026, 03:43 ET Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
May 14, 2026, 10:28 ET AMERICAN-ARAB ANTI-DISCRIMINATION COMMITTEE (ADC) WELCOMES TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS
Los Angeles Board for five years and remains active with the annual Odeh Banquet. Her commitment to ADC is unwavering.ABOUT ADCThe American-Arab Anti-Discrimination Committee (ADC) is the largest Arab American grassroots organization in the United States, founded in 1980 by former
More news about: American-Arab Anti-Discrimination Committee
May 14, 2026, 08:08 ET Piramal Pharma Solutions svela la suite di linker-payload all'avanguardia presso il suo stabilimento di Riverview, Michigan
lo sviluppo e la produzione globale di linker-payload e consentirà ai partner di portare sul mercato terapie complesse come gli anticorpi coniugati (ADC) e altri bioconiugati.MUMBAI, India, 14 maggio 2026 /PRNewswire/
More news about: Piramal Pharma Solutions
May 14, 2026, 07:45 ET Piramal Pharma Solutions dévoile une suite payload-linker ultramoderne dans ses installations de Riverview, Michigan
payload-linkers au niveau mondial et à aider ses partenaires à mettre sur le marché des thérapies complexes telles que les conjugués anticorps-médicaments (ADC) et d'autres bioconjugués.MUMBAI, Inde, 14 mai 2026 /PRNewswire/
More news about: Piramal Pharma Solutions
May 14, 2026, 05:00 ET NOVOSENSE Expands SafeNovo® Portfolio for Automotive Functional Safety Applications
inverters, on-board chargers (OBCs) and DC-DC converters, it integrates up to 19A peak drive capability, ±150kV/μs CMTI, a 12-bit isolated ADC and protection features, helping improve switching robustness, localized sensing and safety integration in SiC and IGBT-based systems operating under
More news about: NOVOSENSE
May 13, 2026, 23:13 ET Piramal Pharma Solutions presenta su suite de última generación para conectores de carga útil
desarrollo y la fabricación global de conectores de carga útil y ayudará a sus socios a comercializar terapias complejas como conjugados anticuerpo-fármaco (ADC) y otros bioconjugados.MUMBAI, India, 14 de mayo de 2026 /PRNewswire/
More news about: Piramal Pharma Solutions
May 13, 2026, 20:00 ET Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small
More news about: Fosun Pharma
May 13, 2026, 10:45 ET Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
abilities, Riverview serves as PPS's dedicated payload-linker supplier, making it critical to ADCelerate™ – PPS's rapid, integrated approach to phase I ADC development.The addition of this payload-linker suite is designed to help PPS accelerate partners' timelines and adapt to evolving market needs.
More news about: Piramal Pharma Solutions
May 13, 2026, 10:37 ET Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
abilities, Riverview serves as PPS's dedicated payload-linker supplier, making it critical to ADCelerate™ – PPS's rapid, integrated approach to phase I ADC development.The addition of this payload-linker suite is designed to help PPS accelerate partners' timelines and adapt to evolving market needs.
More news about: Piramal Pharma Solutions
May 13, 2026, 08:00 ET Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited
More news about: Whitehawk Therapeutics, Inc.
May 12, 2026, 20:00 ET Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 12, 2026, 08:30 ET Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)
Emi-Le is a potentially innovative and differentiated antibody drug conjugate (ADC) directed against B7-H4, a well-characterized target in certain cancers including ACCEmi-Le is currently under clinical development in the U.S. for potential use in aggressive ACC and other
More news about: Servier Pharmaceuticals
May 12, 2026, 08:30 ET Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
Insilico has established over 40 proprietary innovative pipelines and keeps expanding into new modality areas such as peptides, antibody-drug conjugates (ADC), and proteolysis-targeting chimeras (PROTAC).In the field of oligonucleotide therapeutics development, AI is already playing a considerable role
More news about: Insilico Medicine
May 12, 2026, 03:04 ET ACROBiosystems Innovation Day Lands in Zurich: Top Minds Unite to Explore Biotech Frontiers
manufacturing challenges through enzyme immobilization. In their talk "Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production", they presented a patented technology that enhances enzyme stability and reusability. They presented two case studies: immobilizing T7 RNA
More news about: ACROBiosystems Group
May 11, 2026, 07:00 ET Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
therapeutic window and frequent resistance associated with traditional ADC treatments. Furthermore, it offers advantages such as synergistic anti-tumor effects between ADC and IO.World-First TDC Platform ImBiTDC™ (TCE-ADC): Leveraging proprietary antibody platforms and the TOPiKinectics platform,
More news about: Nanjing Leads Biolabs Co., Ltd.
May 08, 2026, 16:15 ET Kestrel Group Reports First Quarter 2026 Financial Results
the AmTrust Quota Share, and a modest reduction in recoveries anticipated under the Loss Portfolio Transfer and Adverse Development Cover Agreement ("LPT/ADC Agreement") with Cavello Bay Reinsurance Limited.The results for the segment's Diversified business largely reflect the ongoing run-off of
More news about: Kestrel Group Ltd
May 08, 2026, 06:40 ET The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 07, 2026, 09:01 ET 再鼎醫藥公布 2026年第一季度財務業績和近期公司進展
年預期重要裡程碑事件預期的臨床開發和數據公布全球管線Zocilurtatug Pelitecan (zoci, 靶向DLL3 ADC) (前稱ZL-1310)一線廣泛期小細胞肺癌：再鼎醫藥將於2026年下半年公布評估zoci聯合療法（聯合阿替利珠單抗±化療）的1期研究的數據讀出，並計劃基於最新數據在2026年推進zoci至注冊性研究階段。
More news about: 再鼎醫藥
May 07, 2026, 09:00 ET Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Marks first ENHANZE® agreement to include ADC targetsCollaboration also includes option for additional future targetsFirst clinical trial projected to initiate in 2026
More news about: Halozyme Therapeutics, Inc.
May 07, 2026, 08:00 ET Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
limited to, statements relating to: the potential therapeutic value and market opportunity for the Company's ADC portfolio; plans related to the Company's development of its portfolio of ADC assets, including the anticipated timing of the submission of an IND in mid-2026 for HWK-206 and commencement
More news about: Whitehawk Therapeutics, Inc.